On the contrary, we observed that application of anti-CTLA-4 (and PD-1 partially) antibodies into the tumor micro-environment inhibits CD4+ and CD8+ cell activity affecting their interaction with breast cancer cells. This evidence concerns the gene CD8A and breast cancer.